Actithera is a radiopharmaceutical company headquartered in Oslo, Norway, and Cambridge, Massachusetts. The company is turning cutting-edge medicinal chemistry, including covalent-targeting, into next-generation radioligand therapies (RLTs) with clear differentiation and large therapeutic window.
